8-K: RxSight Reports Q2 2026 Results, Withdraws Guidance

RxSight, Inc. announced its second quarter 2026 financial results, reporting total revenue of $33.7 million, including $6.5 million from the Alcon collaboration, while product sales declined 19% year-over-year.

Summary

• RxSight, Inc. reported Q2 2026 total revenue of $33.7 million, with $6.5 million attributed to the Alcon strategic collaboration.
• Product sales for Q2 2026 were $27.2 million, a 19% decrease from the prior year, attributed to competitive trialing and consumer sentiment.
• The company sold 24,917 Light Adjustable Lens (LAL) units and 12 Light Delivery Devices (LDD) units in Q2 2026.
• Gross margin for Q2 2026 was 71.2% for product sales (down from 74.9% YoY) and 76.7% including collaboration revenue.
• Total operating expenses were $39.7 million in Q2 2026, a slight increase from $39.2 million in Q2 2025.
• The net loss for Q2 2026 was $12.1 million, or $(0.29) per share, compared to a net loss of $11.8 million, or $(0.29) per share, in Q2 2025.
• Adjusted net loss for Q2 2026 was $4.6 million, or $(0.11) per share, compared to $3.3 million, or $(0.08) per share, in Q2 2025.
• As of June 30, 2026, the company had approximately $209 million in cash, cash equivalents, and short-term investments.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed to slightly negative sentiment due to declining product sales and withdrawn guidance, despite a significant strategic collaboration.

Positives

• Secured a strategic collaboration with Alcon, potentially worth up to $200 million in upfront and milestone payments, plus future royalties.
• Appointed Aziz Mottiwala, an eye care industry leader, as President and Chief Executive Officer.
• Announced development of next-generation Light Adjustable Technology platform (LAL, LAL+, LAL Toric lenses).
• Maintained a strong cash position of approximately $209 million as of June 30, 2026.
• Collaboration revenue contributed $6.5 million to total Q2 revenue.
• Gross margin including collaboration revenue was a strong 76.7%.

Negatives

• Product sales decreased by 19% year-over-year to $27.2 million.
• Product sales were impacted by heightened competitive trialing and continued pressure on consumer sentiment.
• Gross margin on product sales decreased to 71.2% from 74.9% due to inventory-related costs and higher-cost inventory.
• The company withdrew its 2026 financial guidance.
• Net loss increased slightly on an adjusted basis to $4.6 million in Q2 2026 from $3.3 million in Q2 2025.
• Operating expenses remained high at $39.7 million, slightly increasing from the prior year.

Risks

• Heightened competitive trialing and continued pressure on consumer sentiment impacting product sales.
• Inventory-related costs and the flow-through of higher-cost inventory affecting gross margins.
• The company withdrew its 2026 guidance, indicating uncertainty in future performance.
• Potential challenges in strengthening commercial execution and deepening adoption of the technology.
• Risks associated with the development and commercialization of the next-generation Light Adjustable Technology platform.
• Reliance on the success of the strategic collaboration with Alcon for future growth and revenue.

Future Outlook

The company has withdrawn its 2026 financial guidance and plans to resume formal guidance in early 2027. This decision provides flexibility to establish the right operating plan and focus resources on the core business, pipeline, and the Alcon collaboration.

Management Comments

• "It is a privilege to join RxSight and to work alongside the talented team that pioneered an entirely new category in cataract surgery with the only commercially available IOL platform that enables physicians to adjust and personalize vision after surgery," said Aziz Mottiwala, President and Chief Executive Officer of RxSight.
• "The opportunity ahead is significant, and our immediate priority is to strengthen commercial execution, deepen adoption across our installed base and translate the value of adjustability into durable growth."
• "To support those priorities, I have commenced a comprehensive review of the business."
• "While underlying trends remain generally consistent with our prior expectations, withdrawing 2026 guidance gives us the flexibility to establish the right operating plan and focus our resources on the core business, our pipeline and the Alcon collaboration."

Industry Context

StockSavvy.ai notes that the withdrawal of guidance by RxSight, coupled with declining product sales, reflects ongoing market pressures within the ophthalmic device sector, particularly concerning competition and consumer spending. The strategic Alcon collaboration, however, signals a significant move to diversify revenue and leverage adjustability technology in a broader market.

Comparison to Industry Standards

• Competitors in the intraocular lens (IOL) market, such as Johnson & Johnson Vision and Alcon (prior to this collaboration), often report stable or growing product sales in their quarterly earnings, making RxSight's 19% decline notable.
• Gross margins in the medical device sector can vary, but RxSight's product gross margin of 71.2% is generally competitive, though the decline from 74.9% warrants attention.
• The strategic collaboration model, with upfront and milestone payments, is a common approach for medical device companies to de-risk development and expand market reach, similar to partnerships seen with other specialized medical technology firms.

Management Changes

Stakeholder Impact

• Shareholders: Potential negative impact due to withdrawn guidance and declining product sales, offset by the long-term potential of the Alcon collaboration and new technology development.
• Employees: Uncertainty regarding future performance may affect morale; leadership transition could lead to strategic shifts.
• Customers (Physicians): Continued access to innovative technology, but potential concerns about company stability given guidance withdrawal.
• Suppliers: Potential impact on demand for components due to sales trends and strategic shifts.

Next Steps

• Conduct a comprehensive review of the business.
• Strengthen commercial execution.
• Deepen adoption across the installed base.
• Focus resources on the core business, pipeline, and Alcon collaboration.
• Establish a new operating plan.
• Resume formal guidance in early 2027.

Key Dates

Recommendation

The company's product sales are declining, and it has withdrawn its guidance, indicating significant near-term uncertainty. However, the strategic Alcon collaboration and the development of next-generation technology offer substantial long-term potential. A 'hold' recommendation reflects a balance between these near-term headwinds and long-term opportunities, pending clarity from the business review and future guidance.

Keywords

Light Adjustable Lens, Intraocular Lens, Cataract Surgery, Ophthalmic Medical Device, Alcon Collaboration, Presbyopia-Correcting, Medical Technology, Financial Results